-
Thomas F. Deuel, M.D.
Thomas F. Deuel, M.D.
Dr. Deuel is the Presidential Scholar at the Dana Farber Cancer Institute and Adjunct Professor of Molecular and Experimental Medicine and Cell Biology at The Scripps Research Institute. He has served as a Professor of Molecular and Experimental Medicine and Cell Biology, Director of the Division of Molecular Oncology, Department of Molecular and Experimental Medicine, and Director of the Vascular Biology Affinity Group at The Scripps Research Institute. Prior to joining The Scripps Research Institute, Dr. Deuel served as a Professor of Medicine at Harvard Medical School. He is currently a Professor Emeritus at Harvard Medical School. In addition, from 1996 to 2002, Dr. Deuel served as a Director, Division of Growth Regulation at Beth Israel Hospital, Boston, Massachusetts and, prior to that, was a Professor of Medicine and Biochemistry and the head of Oncology Services at the Washington University School of Medicine, St. Louis, Missouri. Dr. Deuel is a member of the Institute of Medicine at the National Academy of Sciences. He has served and continues to serve on numerous scientific advisory boards for various companies. In addition, Dr. Deuel has earned many professional honors and awards. Dr. Deuel holds an M.D. from Columbia University and an A.B. from Princeton University.
Search
Enter your email address to sign up for the Enzon mailing list.
News
-
08-03-2010
Enzon Reports 2nd Quarter 2010...
Enzon Reports 2nd Quarter 2010 Results
-
07-27-2010
Enzon to Release Second Quarte...
Enzon to Release Second Quarter 2010 Earnings on Tuesday, August 3, 2010; Conference Call and Webcast to Follow
-
05-10-2010
Enzon Reports 1st Quarter 201...
Enzon Reports 1st Quarter 2010 Results
-
05-07-2010
Enzon Sets Date of 2010 Annual...
Enzon Sets Date of 2010 Annual Meeting
-
09-30-2008
Enzon's New Oncaspar-IV™ Rec...
Enzon's New Oncaspar-IV™ Receives Orphan Drug Status in the EU
-- Improved version to expand global potential -- -
12-08-2008
Enzon Pharmaceuticals Commence...
Enzon Pharmaceuticals Commences Tender Offer For a Portion of its Debt
-
02-13-2008
Enzon Reports Significant Prog...
Enzon Reports Significant Progress on the Reduction of Its Debt
-
10-29-2007
Enzon Initiates Second Phase 1...
Enzon Initiates Second Phase 1 Study of Its HIF-1 Alpha Antagonist
-
05-10-2010
Enzon Reports 1st Quarter 201...
Enzon Reports 1st Quarter 2010 Results
-
12-22-2009
Enzon Sets Date of Specialty M...
Enzon Sets Date of Specialty Meeting of Stockholders to Approve Sale of Specialty Pharmaceutical Business
--Announces Expiration of Waiting Period Under HSR Act-- -
02-04-2009
Enzon to Present at 11th Annua...
Enzon to Present at 11th Annual BIO CEO & Investor Conference
-
05-20-2008
Enzon Announces Clinical Data...
Enzon Announces Clinical Data From PEG-SN38 and rhMBL Studies at ASCO -- Company will host reception --